

Nadia Haj Mohammad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4640085/publications.pdf>

Version: 2024-02-01

53
papers

1,610
citations

430874

18
h-index

315739

38
g-index

53
all docs

53
docs citations

53
times ranked

1863
citing authors

#	ARTICLE	IF	CITATIONS
1	Robot-assisted Minimally Invasive Thoracoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer. <i>Annals of Surgery</i> , 2019, 269, 621-630.	4.2	436
2	Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). <i>Clinical Cancer Research</i> , 2021, 27, 3351-3359.	7.0	143
3	Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 4352-4360.	1.5	122
4	Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020, 125, 83-93.	2.8	98
5	Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 235-249.	17.8	95
6	Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). <i>BMC Cancer</i> , 2019, 19, 390.	2.6	83
7	Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. <i>Acta Oncologica</i> , 2019, 58, 1048-1055.	1.8	74
8	Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 2840-2849.	2.8	41
9	Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy for esophageal cancer in the upper mediastinum. <i>Journal of Thoracic Disease</i> , 2017, 9, S834-S842.	1.4	32
10	Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands. <i>Annals of Surgery</i> , 2022, 275, 769-775.	4.2	32
11	¹⁸ F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer. <i>JAMA Surgery</i> , 2021, 156, e215340.	4.3	31
12	Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. <i>European Journal of Cancer</i> , 2019, 106, 99-105.	2.8	30
13	Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study. <i>International Journal of Cancer</i> , 2020, 146, 1889-1901.	5.1	29
14	Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018, 103, 214-226.	2.8	28
15	Nationwide treatment and outcomes of perihilar cholangiocarcinoma. <i>Liver International</i> , 2021, 41, 1945-1953.	3.9	28
16	Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 12-29.	6.3	25
17	Pancreatic acinar cell carcinoma is associated with <i>BRCA2</i> germline mutations: a case report and literature review. <i>Cancer Biology and Therapy</i> , 2019, 20, 949-955.	3.4	21
18	A High Lymph Node Yield is Associated with Prolonged Survival in Elderly Patients Undergoing Curative Gastrectomy for Cancer: A Dutch Population-Based Cohort Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2213-2223.	1.5	20

#	ARTICLE	IF	CITATIONS
19	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. <i>Cancers</i> , 2019, 11, 187.	3.7	20
20	A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4045-4045.	1.6	20
21	Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort. <i>Cancers</i> , 2020, 12, 918.	3.7	18
22	Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. <i>European Journal of Surgical Oncology</i> , 2021, 47, 699-707.	1.0	18
23	Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 295-295.	1.6	17
24	Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study. <i>Gastric Cancer</i> , 2020, 23, 579-590.	5.3	16
25	Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review. <i>Gastric Cancer</i> , 2018, 21, 183-195.	5.3	15
26	Tumor volume regression during neoadjuvant chemoradiotherapy for esophageal cancer: a prospective study with weekly MRI. <i>Acta Oncol</i> , 2020, 59, 753-759.	1.8	15
27	Trends in treatment and overall survival among patients with proximal esophageal cancer. <i>World Journal of Gastroenterology</i> , 2019, 25, 6835-6846.	3.3	13
28	Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study. <i>European Journal of Cancer</i> , 2020, 139, 107-118.	2.8	10
29	Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. <i>Acta Oncol</i> , 2020, 59, 705-712.	1.8	9
30	Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. <i>Hpb</i> , 2022, 24, 535-546.	0.3	9
31	Readily available biomarkers predict poor survival in metastatic pancreatic cancer. <i>Biomarkers</i> , 2021, 26, 325-334.	1.9	8
32	SOURCE: Prediction Models for Overall Survival in Patients With Metastatic and Potentially Curable Esophageal and Gastric Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 403-410.	4.9	7
33	Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms. <i>Journal of Surgical Oncology</i> , 2021, 124, 589-597.	1.7	6
34	Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: Incidence and external validation of a prediction model. <i>Radiotherapy and Oncology</i> , 2021, 163, 192-198.	0.6	6
35	First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , 1-8.	4.9	6
36	A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1742-1749.	1.0	5

#	ARTICLE	IF	CITATIONS
37	Frequency of surgical resection after starting neoadjuvant chemoradiotherapy in patients with esophageal cancer: A population-based cohort study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1919-1925.	1.0	4
38	Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. <i>Annals of Thoracic Surgery</i> , 2022, 113, 482-490.	1.3	3
39	Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer. <i>Hpb</i> , 2021, 23, 1886-1896.	0.3	3
40	A population-based study on treatment and outcomes in patients with gastric adenocarcinoma diagnosed with distant interval metastases. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1964-1971.	1.0	3
41	Non-curative gastrectomy for advanced gastric cancer does not result in additional risk of postoperative morbidity compared to curative gastrectomy. <i>Surgical Oncology</i> , 2020, 35, 126-131.	1.6	2
42	A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. <i>Cancers</i> , 2021, 13, 839.	3.7	2
43	A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210855.	3.2	2
44	Refraining from resection in patients with potentially curable gastric carcinoma. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1062-1068.	1.0	1
45	TGF- β 2 and PD-L1 inhibition combined with definitive chemoradiotherapy in esophageal squamous cell carcinoma: A phase II clinical trial (NCT04595149).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4154-TPS4154.	1.6	1
46	SOURCE: Prediction models for overall survival in patients with metastatic and potentially curable esophageal and gastric cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 301-301.	1.6	1
47	Intestinal and tumor microbiome analysis combined with metabolomics of the anti-PD-L1 phase II PERFECT trial for resectable esophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4556-4556.	1.6	1
48	Detecting Interval Distant Metastases With 18F-FDG PET/CT After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer. <i>Clinical Nuclear Medicine</i> , 2022, Publish Ahead of Print, .	1.3	1
49	FA08.01: MORTALITY AND REFRAINMENT FROM ESOPHAGECTOMY IN ESOPHAGEAL CANCER PATIENTS THAT STARTED NEOADJUVANT CHEMORADIOOTHERAPY: A POPULATION-BASED COHORT STUDY. <i>Ecological Management and Restoration</i> , 2018, 31, 15-15.	0.4	0
50	O122 INTERVAL DISTANT METASTASES DURING OR AFTER NEOADJUVANT CHEMORADIOOTHERAPY FOR ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER: A NATION-WIDE POPULATION-BASED COHORT STUDY. <i>Ecological Management and Restoration</i> , 2019, 32, .	0.4	0
51	Survival expressed in best-case, typical and worst-case scenarios for patients with nonmetastatic esophagogastric cancer: A population-based study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 259-259.	1.6	0
52	Anti-PD1, capecitabine, and oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): A proof-of-principle study (AuspiCiOus).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4163-TPS4163.	1.6	0
53	SOURCE beyond first-line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first-line palliative systemic therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4037-4037.	1.6	0